Modality
ADC
MOA
WEE1i
Target
CD20
Pathway
Checkpoint
Pompe
Development Pipeline
Preclinical
~May 2011
→ ~Aug 2012
Phase 1
~Nov 2012
→ ~Feb 2014
Phase 2
~May 2014
→ ~Aug 2015
Phase 3
~Nov 2015
→ ~Feb 2017
NDA/BLA
~May 2017
→ ~Aug 2018
Approved
Nov 2018
→ Dec 2029
ApprovedCurrent
NCT03557718
538 pts·Pompe
2018-11→2029-12·Completed
538 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2029-12-083.7y awayPh3 Readout· Pompe
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Complet…
Catalysts
Ph3 Readout
2029-12-08 · 3.7y away
Pompe
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03557718 | Approved | Pompe | Completed | 538 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-611 | Madrigal Pharma | Approved | CGRP | |
| Cevicapivasertib | Corcept | Phase 2 | CFTR |